Systemic timolol exposure following topical application to infantile hemangiomas - 11/02/20
Doi : 10.1016/j.jaad.2019.02.029
Beth A. Drolet, MD a, ⁎ 
, Felix Boakye-Agyeman, MD b, Barrie Harper, BSMT (ASCP), PMP b, Kristen Holland, MD a, Andrew Lewandowski, PhD c, Nicole Stefanko, MD a, Chiara Melloni, MD, MHS b
on behalf of the
, Felix Boakye-Agyeman, MD b, Barrie Harper, BSMT (ASCP), PMP b, Kristen Holland, MD a, Andrew Lewandowski, PhD c, Nicole Stefanko, MD a, Chiara Melloni, MD, MHS bon behalf of the
Pediatric Trials Network Steering Committee (See Acknowledgments for a listing of committee members.)
Gary Furda, Danny Benjamin, Edmund Capparelli, Gregory L. Kearns, Ian M. Paul, Christoph Hornik, Kelly Wade
a Medical College of Wisconsin, Milwaukee, Wisconsin
b Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
c The Emmes Corporation, Rockville, Maryland
∗Correspondence to: Beth A. Drolet, MD, University of Wisconsin, The School of Medicine and Public Health.University of WisconsinThe School of Medicine and Public Health
| Funding sources: Supported under National Institute of Child Health and Human Development contract HHSN275201000003I for the Pediatric Trials Network (principal investigator, Danny Benjamin). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
| Disclosure: Dr Drolet reports an investigator-initiated trial examining the safety of oral propranolol for treatment of infantile hemangioma that was sponsored by Pierre Fabre. She is owner and co-founder of Peds Derm Development Group, LLC. Dr Boakye-Agyeman, Mr Harper, Dr Holland, Dr Lewandowski, and Dr Stefanko have no conflicts of interest to disclose. |
© 2019
American Academy of Dermatology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Vol 82 - N° 3
P. 733-736 - mars 2020 Regresar al número
Artículo precedente
- Ingenol mebutate to treat lentigo maligna of the head (face and scalp): A prospective, multicenter, single-arm phase 2 trial indicates no benefit
- Henri Montaudié, Florence Le Duff, Catherine Butori, Véronique Hofman, Eric Fontas, Coralie Roger-Cruzel, Philippe Bahadoran, Jean-Luc Perrot, Eve Desmedt, Délphine Legoupil, Thierry Passeron, Jean-Philippe Lacour
- Increased risk of second primary malignancies in patients with mycosis fungoides: A single-center cohort study
- Amrita Goyal, Daniel O'Leary, Kavita Goyal, Nathan Rubin, Kimberly Bohjanen, Maria Hordinsky, Steven T. Chen, Lyn M. Duncan, Georgios Pongas, Aleksandr Lazaryan
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?